Abstract:Serine proteases are classical objects for studies of catalytic and inhibitory mechanisms as well as interesting as therapeutic targets. Since small-molecule serine protease inhibitors generally suffer from specificity problems, peptidic inhibitors, isolated from phage-displayed peptide libraries, have attracted considerable attention. Here, we have investigated the mechanism of binding of peptidic inhibitors to serine protease targets. Our model is upain-1 (CSWRGLENHRMC), a disulfide-bond-constrained competitive inhibitor of human urokinase-type plasminogen activator with a noncanonical inhibitory mechanism and an unusually high specificity. Using a number of modified variants of upain-1, we characterised the upain-1–urokinase-type plasminogen activator complex using X-ray crystal structure analysis, determined a model of the peptide in solution by NMR spectroscopy, and analysed binding kinetics and thermodynamics by surface plasmon resonance and isothermal titration calorimetry. We found that upain-1 changes both main-chain conformation and side-chain orientations as it binds to the protease, in particular its Trp3 residue and the surrounding backbone. The properties of upain-1 are strongly influenced by the addition of three to four amino acids long N-terminal and C-terminal extensions to the core, disulfide-bond-constrained sequence: The C-terminal extension stabilises the solution structure compared to the core peptide alone, and the protease-bound structure of the peptide is stabilised by intrapeptide contacts between the N-terminal extension and the core peptide around Trp3. These results provide a uniquely detailed description of the binding of a peptidic protease inhibitor to its target and are of general importance in the development of peptidic inhibitors with high specificity and new inhibitory mechanisms.

Bicyclic Peptide Inhibitor of Urokinase‐Type Plasminogen Activator: Mode of Action

Structural Principles In The Development Of Cyclic Peptidic Enzyme Inhibitors

The Binding Mechanism of A Peptidic Cyclic Serine Protease Inhibitor

Structural Basis of Specificity of a Peptidyl Urokinase Inhibitor, Upain-1

A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility

Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors Using Non-Natural Arginine Analogs.

Distinctive Binding Modes and Inhibitory Mechanisms of Two Peptidic Inhibitors of Urokinase-Type Plasminogen Activator with Isomeric P1 Residues.

Design of Specific Serine Protease Inhibitors Based on A Versatile Peptide Scaffold: Conversion of A Urokinase Inhibitor to A Plasma Kallikrein Inhibitor

Insight to the Residue in P2 Position Prevents the Peptide Inhibitor from Being Hydrolyzed by Serine Proteases

Cleavage of Peptidic Inhibitors by Target Protease is Caused by Peptide Conformational Transition.

Structure Based Design of Bicyclic Peptide Inhibitors of RbAp48

Macrocyclic inhibitors targeting the prime site of the fibrinolytic serine protease plasmin

Mechanism-Based Macrocyclic Inhibitors of Serine Proteases

Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Biocompatible and Selective Generation of Bicyclic Peptides

Structural Insight into Inactivation of Plasminogen Activator Inhibitor-1 by A Small-Molecule Antagonist

A Specific Plasminogen Activator Inhibitor-1 Antagonist Derived from Inactivated Urokinase

Synthesis of a Weak Basic Upa Inhibitor and Crystal Structure of a Complex with Upa

Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

Structural basis for therapeutic intervention of uPA/uPAR system